Table 2.
Univariate and multivariate analyses for predicting OS of the whole cohort.
| Variables | Patients of the whole cohort | Patients after PSM | ||||||
|---|---|---|---|---|---|---|---|---|
| Univariate analyses | Multivariate analyses | Univariate analyses | Multivariate analyses | |||||
| HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | HR (95%CI) | P value | |
| ECOG-PS score, Ref: PS score of 1 | 0.52 (0.41-0.65) | <0.001 | 0.61 (0.49-0.77) | <0.001 | 0.57 (0.43-0.77) | <0.001 | 0.56 (0.42-0.75) | <0.001 |
| Age, Ref: Age <70 ng/mL | 1.22 (0.85-1.74) | 0.272 | – | – | 0.99 (0.60-1.63) | 0.977 | – | – |
| Genger, Ref: female | 0.97 (0.73-1.28) | 0.852 | – | – | 1.15 (0.75-1.76) | 0.498 | – | – |
| Etiology, Ref: HBV (-) | 0.89 (0.61-1.30) | 0.568 | – | – | 0.85 (0.52-1.39) | 0.541 | – | – |
| AFP, Ref: AFP <400 ng/mL | 1.83 (1.48-2.26) | <0.001 | 1.67 (1.34-1.34) | <0.001 | 1.79 (1.34-2.39) | <0.001 | 1.62 (1.21-2.17) | <0.001 |
| Tumor number, Ref: n=1 | 1.02 (0.54-1.92) | 0.931 | – | – | 0.25 (0.03-1.85) | 0.178 | – | – |
| Tumor size, Ref: size ≤5 cm | 2.43 (1.97-3.00) | <0.001 | 2.13 (1.72-2.64) | <0.001 | 2.52 (1.83-3.46) | <0.001 | 2.42 (1.76-3.33) | <0.001 |
| Albumin, Ref: Albumin >35 g/L | 1.66 (1.18-2.33) | 0.003 | 1.67 (1.19-2.35) | 0.003 | 1.28 (0.75-2.17) | 0.351 | – | – |
| TBIL, Ref: TBIL >17.1 μmol/L | 1.02 (0.84-1.27) | 0.838 | – | – | 0.99 (0.97-1.01) | 0.600 | – | – |
| AST, per 1U/L increase | 1.00 (0.99-1.00) | 0.692 | – | – | 1.00 (0.99-1.00) | 0.913 | – | – |
| ALT, per 1U/L increase | 0.99 (0.99-1.00) | 0.505 | – | – | 0.99 (0.99-1.00) | 0.540 | – | – |
| WBC, per 1×109/L increase | 1.01 (0.97-1.04) | 0.526 | – | – | 1.01 (0.95-1.07) | 0.574 | – | – |
| BUN, per mmol/L increase | 0.97 (0.91-1.02) | 0.281 | – | – | 0.90 (0.82-0.99) | 0.039 | 0.92 (0.85-1.01) | 0.084 |
| PLT, per 1×109/L increase | 1.00 (0.99-1.00) | 0.849 | – | – | 1.00 (0.99-1.00) | 0.654 | – | – |
| INR, per 1 increase | 1.10 (0.69-1.73) | 0.681 | – | – | 0.94 (0.47-1.87) | 0.681 | – | – |
After a propensity score matching (PSM), there were 342 patients in PS stratifications.
HR, hazard ratio; CI, confidence interval; ECOG, Eastern Cooperative Oncology Group; PS, performance status; HBV, hepatitis B virus; AFP, alpha-fetoprotein; TBIL, total bilirubin; AST, aspartate aminotransferase; ALT, alamine aminotransferase; WBC white blood cell; BUN, blood urea nitrogen; PLT, platelet count; INR, international normalized ratio.